Tags

Type your tag names separated by a space and hit enter

Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain.
Eur J Pharmacol. 2011 Mar 25; 655(1-3):46-51.EJ

Abstract

Milnacipran, a serotonin/norepinephrine reuptake inhibitor (SNRI), has shown efficacy against several chronic pain conditions, including fibromyalgia. Here, we evaluated, in rats, its anti-allodynic effects following acute or sub-chronic treatment in a model of neuropathic pain (chronic constriction injury, CCI, of the sciatic nerve). Amitriptyline, a tricyclic antidepressant active pre-clinically and clinically against neuropathic pains, was added as a comparison compound. Upon acute i.p. administration, milnacipran was potently efficacious in the CCI model. It significantly reduced thermal allodynia in the cold (4°C) plate test (MED=2.5mg/kg), and attenuated mechanical allodynia in the von Frey filaments test (MED=10mg/kg). Given sub-chronically (7day, b.i.d.), milnacipran was effective at 10mg/kgi.p. in both tests. Acute amitriptyline (10mg/kgi.p.) was efficacious against mechanical, but less so against cold allodynia; under sub-chronic conditions, it was only active against mechanical allodynia. These data show that milnacipran is as efficacious as the reference compound amitriptyline in a pre-clinical model of injury-induced neuropathy, and demonstrate for the first time that it is active acutely and sub-chronically against cold allodynia. They also suggest that milnacipran has the potential to alleviate allodynia associated with nerve compression-induced neuropathic pain in the clinic (for example following discal hernia, avulsion or cancer-induced tissue damage).

Authors+Show Affiliations

Department of Neuroscience (Pharmacology and Psychiatry), Faculty of Medicine, University of Cadiz, 11003 Cadiz, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21277295

Citation

Berrocoso, Esther, et al. "Evaluation of Milnacipran, in Comparison With Amitriptyline, On Cold and Mechanical Allodynia in a Rat Model of Neuropathic Pain." European Journal of Pharmacology, vol. 655, no. 1-3, 2011, pp. 46-51.
Berrocoso E, Mico JA, Vitton O, et al. Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. Eur J Pharmacol. 2011;655(1-3):46-51.
Berrocoso, E., Mico, J. A., Vitton, O., Ladure, P., Newman-Tancredi, A., Depoortère, R., & Bardin, L. (2011). Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. European Journal of Pharmacology, 655(1-3), 46-51. https://doi.org/10.1016/j.ejphar.2011.01.022
Berrocoso E, et al. Evaluation of Milnacipran, in Comparison With Amitriptyline, On Cold and Mechanical Allodynia in a Rat Model of Neuropathic Pain. Eur J Pharmacol. 2011 Mar 25;655(1-3):46-51. PubMed PMID: 21277295.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. AU - Berrocoso,Esther, AU - Mico,Juan-Antonio, AU - Vitton,Olivier, AU - Ladure,Philippe, AU - Newman-Tancredi,Adrian, AU - Depoortère,Ronan, AU - Bardin,Laurent, Y1 - 2011/01/28/ PY - 2010/08/24/received PY - 2010/12/10/revised PY - 2011/01/12/accepted PY - 2011/2/1/entrez PY - 2011/2/1/pubmed PY - 2011/7/13/medline SP - 46 EP - 51 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 655 IS - 1-3 N2 - Milnacipran, a serotonin/norepinephrine reuptake inhibitor (SNRI), has shown efficacy against several chronic pain conditions, including fibromyalgia. Here, we evaluated, in rats, its anti-allodynic effects following acute or sub-chronic treatment in a model of neuropathic pain (chronic constriction injury, CCI, of the sciatic nerve). Amitriptyline, a tricyclic antidepressant active pre-clinically and clinically against neuropathic pains, was added as a comparison compound. Upon acute i.p. administration, milnacipran was potently efficacious in the CCI model. It significantly reduced thermal allodynia in the cold (4°C) plate test (MED=2.5mg/kg), and attenuated mechanical allodynia in the von Frey filaments test (MED=10mg/kg). Given sub-chronically (7day, b.i.d.), milnacipran was effective at 10mg/kgi.p. in both tests. Acute amitriptyline (10mg/kgi.p.) was efficacious against mechanical, but less so against cold allodynia; under sub-chronic conditions, it was only active against mechanical allodynia. These data show that milnacipran is as efficacious as the reference compound amitriptyline in a pre-clinical model of injury-induced neuropathy, and demonstrate for the first time that it is active acutely and sub-chronically against cold allodynia. They also suggest that milnacipran has the potential to alleviate allodynia associated with nerve compression-induced neuropathic pain in the clinic (for example following discal hernia, avulsion or cancer-induced tissue damage). SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/21277295/Evaluation_of_milnacipran_in_comparison_with_amitriptyline_on_cold_and_mechanical_allodynia_in_a_rat_model_of_neuropathic_pain_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(11)00062-8 DB - PRIME DP - Unbound Medicine ER -